ERBB2 and breast carcinoma: The biomarkersfor subtyping (HER2, ER, PR) and others associated with breast cancer(e.g., folate receptor) could be used to target MnO nanoparticles;however, these biomarkers are either in the cell nucleus20,21 or expressed at relatively low rates.22,23